Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials

[1] Gennari R(2004)Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients Cancer 101 1302-1310

[2] Hurria A(2015)Improving the evidence base for treating older adults with Cancer: American Society of Clinical Oncology statement J Clin Oncol 33 3826-3833

[3] Higgins JP(2003)Measuring inconsistency in meta-analyses BMJ 327 557-560

[4] van Houwelingen HC(2002)Advanced methods in meta-analysis: multivariate approach and meta-regression Stat Med 21 589-624

[5] Arends LR(2013)Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncol 14 989-998

[6] Stijnen T(2016)Phase III trial evaluating Letrozole as first-line endocrine therapy with or without Bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast Cancer: CALGB 40503 (Alliance) J Clin Oncol 34 2602-2609

[7] Johnston SR(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-35

[8] Dickler MN(2016)Palbociclib and Letrozole in advanced breast Cancer N Engl J Med 375 1925-1936

[9] Finn RS(2016)Ribociclib as first-line therapy for HR-positive, advanced breast Cancer N Engl J Med 375 1738-1748

[10] Finn RS(2017)MONARCH 3: Abemaciclib as initial therapy for advanced breast Cancer J Clin Oncol 35 3638-3646

[1] Gennari R(2004)Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients Cancer 101 1302-1310

[2] Hurria A(2015)Improving the evidence base for treating older adults with Cancer: American Society of Clinical Oncology statement J Clin Oncol 33 3826-3833

[3] Higgins JP(2003)Measuring inconsistency in meta-analyses BMJ 327 557-560

[4] van Houwelingen HC(2002)Advanced methods in meta-analysis: multivariate approach and meta-regression Stat Med 21 589-624

[5] Arends LR(2013)Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncol 14 989-998

[6] Stijnen T(2016)Phase III trial evaluating Letrozole as first-line endocrine therapy with or without Bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast Cancer: CALGB 40503 (Alliance) J Clin Oncol 34 2602-2609

[7] Johnston SR(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-35

[8] Dickler MN(2016)Palbociclib and Letrozole in advanced breast Cancer N Engl J Med 375 1925-1936

[9] Finn RS(2016)Ribociclib as first-line therapy for HR-positive, advanced breast Cancer N Engl J Med 375 1738-1748

[10] Finn RS(2017)MONARCH 3: Abemaciclib as initial therapy for advanced breast Cancer J Clin Oncol 35 3638-3646